Context Therapeutics (NASDAQ:CNTX) Upgraded to “Sell” at Wall Street Zen

Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Sunday.

Several other equities analysts have also issued reports on CNTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a report on Monday, April 20th. Piper Sandler boosted their target price on Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 24th. Maxim Group reduced their target price on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, June 16th. Guggenheim reiterated a “buy” rating and issued a $5.00 price target on shares of Context Therapeutics in a research note on Tuesday, March 24th. Finally, D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a report on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $6.17.

Context Therapeutics Trading Up 9.8%

Shares of NASDAQ:CNTX traded up $0.06 during trading on Friday, reaching $0.65. The stock had a trading volume of 3,904,766 shares, compared to its average volume of 4,931,461. Context Therapeutics has a one year low of $0.55 and a one year high of $3.62. The company has a market capitalization of $59.99 million, a P/E ratio of -1.55 and a beta of 1.75. The firm’s 50-day simple moving average is $1.60 and its 200 day simple moving average is $2.02.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.03. Equities research analysts forecast that Context Therapeutics will post -0.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CNTX. XTX Topco Ltd grew its stake in Context Therapeutics by 858.8% during the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after purchasing an additional 91,008 shares during the last quarter. Quadrature Capital Ltd purchased a new position in shares of Context Therapeutics in the fourth quarter worth about $68,000. Marshall Wace LLP lifted its holdings in shares of Context Therapeutics by 7,153.7% during the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock worth $3,812,000 after purchasing an additional 2,557,448 shares during the period. State Street Corp lifted its holdings in shares of Context Therapeutics by 8.5% during the fourth quarter. State Street Corp now owns 165,607 shares of the company’s stock worth $243,000 after purchasing an additional 13,000 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Context Therapeutics by 58.8% in the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after buying an additional 188,202 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.